Is Nuvei (TSX:NVEI) Stock a Buy?

Nuvei (TSX:NVEI)(NASDAQ:NVEI) stock continues to climb on the back of better-than-expected results and an increased financial forecast.

| More on:

Key points

  • Nuvei’s (TSX:NVEI)(NASDAQ:NVEI) better-than-expected third-quarter results led to a slew of analyst increased target prices.
  • The company upped its financial forecast, aided in part by acquisitions.
  • Nuvei stock continues to look cheap for Motley Fool investors even with the continuously increasing share price.

Nuvei has taken investors on quite the ride this year. Shares of Nuvei stock climbed 172% to reach all-time highs between January and September of this year. However, since then the stock has stalled, now trading at around $140 as of rising.

Nuvei stock is one of the many e-commerce-related companies investors aren’t sure about these days. You could see it continue soaring, but the rise of vaccination rates has some thinking twice. Yet analysts continue to raise their guidance for this tech stock for the company worth $19.87 billion.

Earnings

Analysts didn’t expect Nuvei stock to post the successful earnings it did recently, causing many to increase their target prices. This came from the company posting several strong acquisitions that brought in revenue, along with stable organic growth.

Nuvei stock reported quarterly revenue of US$184 million during the last quarter, up 97% year over year and beating analyst estimates of around US$180 million. It also reported adjusted EBITDA of US$81 million, also beating estimates.

But while analysts increased their guidance for Nuvei stock, there was a word of warning that Motley Fool investors should pay attention to. The revenue growth won’t go away exactly, but it may stall in the medium term.

Medium-term growth may stall

The stall can be attributed to two factors, analysts say. First, there is the pandemic. Less use of online services could lead to lower organic growth for Nuvei stock. As one analyst stated, there has been a “re-rating” during the pandemic, and this has led to a transition back towards pre-pandemic levels.

Second to the pandemic is the growth through acquisitions. Nuvei stock continues to pick up companies, adding clients thanks to its strong cash position. But this growth is a somewhat temporary matter and is likely to slow in the medium-term outlook. So, that would put the stock in fairly valued territory, according to some analysts.

So, while the company may continue to outperform the rest of the industry, Motley Fool investors may want to pay attention before buying in bulk.

The road ahead

Nuvei stock reported some strong results with some key points to pay attention to. It continues to increase its cash balance, almost double where it was last year. Furthermore, it continues to expand on a global basis, with use in all of its four regions of North America, Europe, the Middle East and Africa, and Asia-Pacific increasing in the double- to triple-digit range.

The company also entered the online gaming and sports betting industry, with several new customer wins to expand in this burgeoning area as well, both in the United States and Netherlands. This, of course, is on top of the several acquisitions it made during the last quarter and year and a Nasdaq IPO.

Nuvei stock believes it can increase its previous targets and achieve between US$90 and US$91 billion for the 2021 full year, up from US$88-US$91 billion. Adjusted EBITDA grew immensely as well to between US$312 and US$316 million. The company believes its growing sales pipeline and sales channel will continue to grow in the medium and long term for investors, so time will only tell.

For Motley Fool investors looking at the stock, it’s a difficult time to jump on board. Shares are down from all-time highs, up 112% year to date and down from 172%. And the P/E ratio is incredibly high at 138 as of writing. Yet with analysts estimating a target price of $164, that’s a potential upside of 17% as of writing — something that can’t just be ignored for high-growth seekers.

Fool contributor Amy Legate-Wolfe has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Nuvei Corporation.

More on Tech Stocks

Quantum Computing Words on Digital Circuitry
Tech Stocks

Investors: Canada’s Government Is Backing Quantum Computing

Here’s what the Canadian government’s major new investment in quantum computing means for investors.

Read more »

top TSX stocks to buy
Tech Stocks

As the TSX Breaks Higher, These Canadian Stocks Look Poised to Win in 2026

Three Canadian stocks with high-velocity growth potential could be among TSX’s winning investments in 2026.

Read more »

warehouse worker takes inventory in storage room
Tech Stocks

Outlook for Shopify Stock in 2026

Shopify has delivered another strong year, but the bigger question now is whether its expanding platform and AI push can…

Read more »

AI concept person in profile
Tech Stocks

TFSA Wealth Plan: Create $1 Million With a Single Canadian Stock

Topicus could help build a $1 million TFSA thanks to sticky software, recurring revenue, and a disciplined acquisition engine if…

Read more »

AI image of a face with chips
Tech Stocks

The Market Sold BlackBerry After Its Earnings Beat – Here’s Why I’d Buy More

BlackBerry (TSX:BB) beat expectations again, yet the stock slipped, and a closer look at its latest numbers shows why that…

Read more »

Young Boy with Jet Pack Dreams of Flying
Tech Stocks

These 2 TSX Stocks Look Set to Soar in 2026 and Beyond

2 TSX stocks to buy for 2026: MDA Space (MDA) offers deep value with a massive backlog, while Descartes Systems…

Read more »

Canada Day fireworks over two Adirondack chairs on the wooden dock in Ontario, Canada
Tech Stocks

1 Dividend-Paying Tech Stock I’d Buy Before Touching Shopify

Constellation Software (TSX:CSU) might be a better value than other Canadian tech stars in 2026.

Read more »

doctor uses telehealth
Tech Stocks

Ready for Healthcare AI? Put WELL Health Technologies Plus 2 More on Your Watchlist

Three Canadian companies are sound investment options as AI adoption in the healthcare sector accelerates.

Read more »